Antifungal Drugs in Newborns and Children

Area of Science:

• Pediatric Infectious Diseases
• Mycology
• Clinical Pharmacology

Background:

• Invasive fungal infections (IFIs) are a major cause of illness and death in pediatric patients.
• Prompt diagnosis and appropriate antifungal therapy are crucial for improving outcomes.
• Current pediatric antifungal dosing guidelines often lack robust safety and efficacy data.

Purpose of the Study:

• To review and synthesize existing literature on antifungal drug dosing in pediatric populations.
• To identify gaps in knowledge regarding the safety and efficacy of antifungals in children.
• To highlight the need for further research in pediatric antifungal pharmacotherapy.

Main Methods:

• Systematic literature search of relevant databases (e.g., PubMed, Embase).
• Inclusion criteria focused on studies reporting antifungal dosing, pharmacokinetics, safety, and efficacy in infants and children.
• Data extraction and qualitative synthesis of findings.

Main Results:

• Limited high-quality studies specifically addressing pediatric antifungal dosing were identified.
• Significant variability exists in reported dosing regimens across different studies and age groups.
• Comprehensive safety and efficacy data in pediatric populations remain scarce.

Conclusions:

• There is a critical need for more research to establish evidence-based antifungal dosing strategies for pediatric patients.
• Standardized dosing protocols and further clinical trials are essential to optimize treatment and improve outcomes for children with IFIs.
• Addressing data gaps will enhance the safe and effective management of invasive fungal infections in pediatric care.